Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamera J Corte

Showing results (91-100 of 154) with videos related to

Pageof 16
Sort By:
Respirology (Carlton, Vic.)|April 2, 2026
Deep-Learning Algorithm Diagnostic Support for Usual Interstitial Pneumonia Pattern Recognition in Fibrotic Interstitial Lung DiseaseCaitlin C Fermoyle, John A Mackintosh, Vidya Navaratnam, et al.
American Journal of Respiratory and Critical Care Medicine|December 7, 2020
Cryobiopsy for Identification of Usual Interstitial Pneumonia and Other Interstitial Lung Disease Features. Further Lessons from COLDICE, a Prospective Multicenter Clinical TrialWendy A Cooper, Annabelle Mahar, Jeffrey L Myers, et al.
The Lancet. Respiratory Medicine|August 17, 2019
Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b studySteven D Nathan, Jürgen Behr, Harold R Collard, et al.
Thorax|July 15, 2020
Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Australia: case-control studyMichael J Abramson, Tsitsi Murambadoro, Sheikh M Alif, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 13, 2023
A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis-Associated Interstitial Lung Disease: A Multicenter, Observational Cohort StudyAdelle S Jee, Iain Stewart, Peter Youssef, et al.
Respirology (Carlton, Vic.)|February 7, 2017
Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF RegistryIan N Glaspole, Sally A Chapman, Wendy A Cooper, et al.
Respirology (Carlton, Vic.)|October 28, 2024
Diagnosis and management of hypersensitivity pneumonitis in adults: A position statement from the Thoracic Society of Australia and New ZealandHayley Barnes, Tamera J Corte, Gregory Keir, et al.
Physical Therapy|June 29, 2024
Effect of a 4-Week Telerehabilitation Program for People With Post-COVID Syndrome on Physical Function and Symptoms: Protocol for a Randomized Controlled TrialJack M Reeves, Lissa M Spencer, Ling-Ling Tsai, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|May 1, 2020
The supportive care needs of people living with pulmonary fibrosis and their caregivers: a systematic reviewJoanna Y T Lee, Gabriella Tikellis, Tamera J Corte, et al.
BMJ Open Respiratory Research|December 31, 2021
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA<sub>1</sub>) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)Tamera J Corte, Lisa Lancaster, Jeffrey J Swigris, et al.
Pageof 16

Showing results (91-100 of 154) with videos related to

Sort By:
Pageof 16
Respirology (Carlton, Vic.)|April 2, 2026
Deep-Learning Algorithm Diagnostic Support for Usual Interstitial Pneumonia Pattern Recognition in Fibrotic Interstitial Lung DiseaseCaitlin C Fermoyle, John A Mackintosh, Vidya Navaratnam, et al.
American Journal of Respiratory and Critical Care Medicine|December 7, 2020
Cryobiopsy for Identification of Usual Interstitial Pneumonia and Other Interstitial Lung Disease Features. Further Lessons from COLDICE, a Prospective Multicenter Clinical TrialWendy A Cooper, Annabelle Mahar, Jeffrey L Myers, et al.
The Lancet. Respiratory Medicine|August 17, 2019
Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b studySteven D Nathan, Jürgen Behr, Harold R Collard, et al.
Thorax|July 15, 2020
Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Australia: case-control studyMichael J Abramson, Tsitsi Murambadoro, Sheikh M Alif, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 13, 2023
A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis-Associated Interstitial Lung Disease: A Multicenter, Observational Cohort StudyAdelle S Jee, Iain Stewart, Peter Youssef, et al.
Respirology (Carlton, Vic.)|February 7, 2017
Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF RegistryIan N Glaspole, Sally A Chapman, Wendy A Cooper, et al.
Respirology (Carlton, Vic.)|October 28, 2024
Diagnosis and management of hypersensitivity pneumonitis in adults: A position statement from the Thoracic Society of Australia and New ZealandHayley Barnes, Tamera J Corte, Gregory Keir, et al.
Physical Therapy|June 29, 2024
Effect of a 4-Week Telerehabilitation Program for People With Post-COVID Syndrome on Physical Function and Symptoms: Protocol for a Randomized Controlled TrialJack M Reeves, Lissa M Spencer, Ling-Ling Tsai, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|May 1, 2020
The supportive care needs of people living with pulmonary fibrosis and their caregivers: a systematic reviewJoanna Y T Lee, Gabriella Tikellis, Tamera J Corte, et al.
BMJ Open Respiratory Research|December 31, 2021
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA<sub>1</sub>) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)Tamera J Corte, Lisa Lancaster, Jeffrey J Swigris, et al.
Pageof 16